Advances in Prostate Imaging, Detection and Ablative Treatment of Prostate Cancer

Friday, June 16–Saturday, June 17, 2017
New York City

Register online at: med.nyu.edu/cme/prostate
CME Information

**COURSE DESCRIPTION**
The primary goal of this conference is to provide the urologist and radiologist with a comprehensive review of advances in prostate imaging, biopsy, assessment of prostate cancer aggressiveness and minimally invasive ablative therapy (MIAT) of prostate cancer that have a direct impact on disease management. The course is designed for practicing and academic urologists and radiologists who are interested in learning about and adopting multi-parametric MRI imaging, targeted prostate biopsy, molecular risk assessment and MIAT for managing prostate cancer. Optimizing the selection of candidates and post-ablation management of these novel treatment options will also be emphasized.

The course will be organized into sessions focusing on prostate imaging, prostate biopsy, disease risk stratification and MIAT. The information will be disseminated via lectures, case discussions and panel discussions.

The educational focus is designed to optimize selection of candidates and delivery of MIAT for prostate cancer by: identifying the ideal biopsy strategy in order to reliably assess the extent and biological aggressiveness of the disease; to discuss novel tumor markers for improving risk stratification; to apply the latest advances in imaging of prostate cancer in order to improve assessment of the site and extent of clinically significant disease; enable target biopsies; critically examine the most promising approaches for ablating prostate cancer and presenting technological pearls to maximize outcomes following minimally invasive ablative treatment of prostate cancer.

**TARGET AUDIENCE**
The course is designed for practicing and academic urologists and radiologists who are interested in learning about and possibly adopting multi-parametric MRI, targeted biopsy, molecular risk assessment and minimally invasive ablative therapies for detecting and treating prostate cancer. The safe and effective implementation of MIAT requires not only an understanding of ablative strategies, but also patient selection which is influenced by prostate imaging and prostate biopsy techniques. In addition, the optimal post-treatment management to ensure oncological control will also be discussed.

**EDUCATIONAL OBJECTIVES**
At the conclusion of this activity, participants should be able to:

- Evaluate the merits of 12 core random systematic biopsy vs. MRI guided biopsy to assess site and risk of prostate cancer. In addition, clinicians should be able to use mpMRI to identify cases where prostate biopsy may be safely omitted
- Describe the sequences obtained during a prostatic mpMRI, including contrast enhancement and diffusion weighted imaging. In addition, they should be able to assess the optimal timing for performing mpMRI post-biopsy or post-ablation
- Describe the ablative properties of HIFU, cryotherapy, laser, radio-frequency and VPT, differentiate between focal, hemi-ablation and subtotal gland ablation and select the most appropriate minimally invasive ablative therapy for management of patients with localized prostate cancer
- Evaluate and differentiate between different approaches for using MRI guided prostate biopsy
- Discuss factors that enhance effectiveness of minimally invasive procedures and establish and utilize treatment strategies that decrease complications
- Describe and analyze the various tools that are commercially available for assessing the molecular signature of prostate cancers
options in order to select the most appropriate treatment strategy and source of ablative energy. It is also important that in learning about the multiple options, clinicians appreciate the reasons why the faculty select specific ablative energy sources and technique in a case-based setting. Random TRUS guided biopsy has been shown to over-detect insignificant prostate cancer and under-detect significant prostate cancer. There is new evidence that MRI guided biopsy using cognitive co-registration, co-registration with US or in bore biopsy increases specificity of prostate biopsy without decreasing sensitivity for detecting clinically significant disease. Clinicians need to know the relative benefits of these approaches for improving accuracy of prostate biopsy. Minimally invasive ablative therapies are technically demanding procedures and clinicians need to be experienced with the equipment and procedures before incorporating them into practice. Clinicians need to learn surgical pearls from experts in the field in order to avoid complications and ensure the best outcomes.

The Gleason score has tremendous limitations for assessing the aggressiveness of prostate cancer. There is increasing evidence that molecular signatures provide insights about the biology of cancers and may represent a useful tool for assessing the risk of prostate cancers, thereby offering "personalized" medicine.
Faculty

Course Director

Herbert Lepor, MD
Professor and Martin Spatz Chair
Department of Urology
Professor, Department of Biochemistry and Molecular Pharmacology
NYU School of Medicine
Chief, Urology
NYU Langone Medical Center

Guest Faculty

Mark Emberton, MD, FRCS
Professor of Interventional Oncology
Director, Division of Surgery and Interventional Science
University College London
London, UK

Jurgen J. Futterer, MD, PhD
Associate Professor of Radiology
Radboud University
Nijmegen, The Netherlands

Eric A. Klein, MD
Professor of Surgery
Chairman, Glickman Urological and Kidney Institute
Cleveland Clinic
Cleveland, OH

Peter A. Pinto, MD
Head, Prostate Cancer Section
Director, Fellowship Program
Urologic Oncology Branch
National Cancer Institute
Bethesda, MD

Stephen M. Scionti, MD
Director, Scionti Prostate Center
Medical Director Vituro Health
Sarasota, FL

Edouard Trabulsi, MD, FACS
Professor and Vice Chair of Urology
Sidney Kimmel Medical College
at Thomas Jefferson University
Philadelphia, PA

NYU School Of Medicine Faculty

Marc A. Bjurlin, DO
Clinical Assistant Professor of Urology
Director, Urologic Oncology
NYU Lutheran

Stacy Loeb, MD, MSc
Assistant Professor of Urology and Population Health

Samir S. Taneja, MD
The James M. Neissa and Janet Riha Neissa Professor of Urologic Oncology
Professor of Radiology
Director, Division of Urologic Oncology

James S. Wysock, MD, MS
Assistant Professor of Urology
Chief of Urology Service, NYC Health + Hospitals/Bellevue

3T Multi-Parametric Prostate MRI Showing a Dominant Cancer
ACREDITATION STATEMENT
The NYU Post-Graduate Medical School is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
The NYU Post-Graduate Medical School designates this live activity for a maximum of 14.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE STATEMENT
The NYU Post-Graduate Medical School adheres to ACCME accreditation requirements and policies, including the Standards for Commercial Support regarding industry support of continuing medical education. In order to resolve any identified conflicts of interest, disclosure information is provided during planning process to ensure resolution of any identified conflicts. Disclosure of faculty and commercial relationships, as well as the discussion of unlabeled or unapproved use of any drug, device or procedure by the faculty, will be fully noted at the meeting.

HOTEL ACCOMMODATIONS
Rooms are in very heavy demand in New York City; we urge you to make your reservations early. You may obtain a list of hotels located near NYU Langone Medical Center by visiting our website: med.nyu.edu/cme/travel

PARKING
For information, please visit nyulangone.org/locations/tisch-hospital/parking
We cannot validate parking for registrants.

REFUND POLICY
In order to request a refund, you must email maria.mercado@nyumc.org no later than 14 days prior to the first day of the course. An administrative fee of $75 will be deducted from your refund. Cancellations or no-shows after this date are not eligible for a refund.

COURSE CANCELLATION POLICY
If a course is cancelled due to inclement weather, insufficient enrollment, or any other reason, NYU PGMS will refund registration fees in full. NYU PGMS will provide at least two weeks’ advance notice if cancelling due to insufficient enrollment and as soon as possible in all other circumstances. NYU PGMS is not responsible for any airfare, hotel, or other non-cancellable costs incurred by the registrant.

LOCATION
NYU Langone Medical Center
550 First Avenue
Alumni Hall, Classroom B
New York, NY 10016

CONTACT INFORMATION
NYU Post-Graduate Medical School
Tel: 212-263-5295
Fax: 212-263-5293
Email: cme@nyumc.org

COURSE FEES
Early Bird
(Ends on 3/22/2017 at 11:59pm)
Full: $550
Reduced: $520*

Regular
Full: $625
Reduced: $550*

* Reduced Fee applies to: NYU School of Medicine alumni; former residents and fellows; physicians-in-training with letter of certification from the Chief of Service; physicians employed by the Department of Veterans Affairs Medical Center; full-time active military personnel; retired physicians; and all other non-physician healthcare professionals.

After 12pm on June 14, 2017, only onsite registration is available; provided the course has not reached capacity. Onsite registrants will incur an additional $20 charge and will receive a receipt by email in 1-2 weeks.

PROVIDED BY
The NYU Post-Graduate Medical School
# Program

**Friday**  
**June 16**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:15 AM</td>
<td>Registration and Continental Breakfast</td>
<td></td>
</tr>
<tr>
<td>8:00</td>
<td>Overview: Advances in Screening, Detection and Treatment of Prostate Cancer</td>
<td>Herbert Lepor, MD</td>
</tr>
<tr>
<td></td>
<td>8:30 Prostatic MRI: State of the Art</td>
<td>Jurgen J. Futterer, MD, PhD</td>
</tr>
<tr>
<td></td>
<td>9:10 Interpreting MRI of the Prostate</td>
<td>Mark Emberton, MD, FRCS</td>
</tr>
<tr>
<td></td>
<td>9:50 MRI of the Prostate: How it Influences Management of Prostate Cancer</td>
<td>Samir S. Taneja, MD</td>
</tr>
<tr>
<td></td>
<td>10:30 Coffee Break</td>
<td></td>
</tr>
<tr>
<td>10:45</td>
<td>Optimizing Grey Scale Prostate Ultrasound</td>
<td>Stephen M. Scionti, MD</td>
</tr>
<tr>
<td>11:00</td>
<td>Advances in Prostate Ultrasound: Multi-Parametric US</td>
<td>Edouard Trabulsi, MD, FACS</td>
</tr>
<tr>
<td>11:30</td>
<td>Prostate Imaging: Cases</td>
<td>Mark Emberton, MD, FRCS</td>
</tr>
<tr>
<td>12:00 PM</td>
<td>Lunch (on your own)</td>
<td></td>
</tr>
<tr>
<td>1:00</td>
<td>In Bore MRI Guided Prostate Biopsy: Technique and Feasibility</td>
<td>Jurgen J. Futterer, MD, PhD</td>
</tr>
<tr>
<td></td>
<td>Commercially Available 3D Co-Registration Systems</td>
<td>James S. Wysock, MD, MS</td>
</tr>
<tr>
<td>2:00</td>
<td>MRI: US Fusion Target Biopsy (MRFTB): The NCI Experience</td>
<td>Peter A. Pinto, MD</td>
</tr>
<tr>
<td>2:40</td>
<td>MRFTB: The NYU Langone Experience</td>
<td>Samir S. Taneja, MD</td>
</tr>
<tr>
<td>3:20</td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>3:35</td>
<td>Artemis MRFTB: Technical Pearls</td>
<td>James S. Wysock, MD, MS</td>
</tr>
<tr>
<td>3:50</td>
<td>Uro-Nav MRFTB: Technical Pearls</td>
<td>Peter A. Pinto, MD</td>
</tr>
<tr>
<td>4:15</td>
<td>Natural Hx of Bx Negative MRI Lesion, Role of Systematic Biopsy In the Era of MRFTB</td>
<td>Herbert Lepor, MD</td>
</tr>
<tr>
<td>4:35</td>
<td>Moderator: Samir S. Taneja, MD</td>
<td></td>
</tr>
<tr>
<td>5:15 PM</td>
<td>Question and Answer, Panel Discussion, Case Presentations</td>
<td>Jurgen J. Futterer, MD, PhD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Herbert Lepor, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Peter A. Pinto, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Stephen M. Scionti, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Samir S. Taneja, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>James S. Wysock, MD, MS</td>
</tr>
<tr>
<td>5:15 PM</td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>
Saturday
June 17

7:30 AM  Registration and Continental Breakfast

8:00  Active Surveillance: The Solution for Managing Low Risk PCa?
Stacy Loeb, MD, MSc

8:30  Negative Systematic Biopsy and Rising PSA
Herbert Lepor, MD

8:50  Differentiating Molecular Risk Assessments of Prostate Cancer
Marc A. Bjurlin, DO

9:20  Molecular Risk Assessment of Low/Intermediate Risk Prostate Cancer
Eric A. Klein, MD

9:50  Is There a Role for Minimally Invasive Ablative Treatment of Prostate Cancer?
Herbert Lepor, MD

10:15  Coffee Break

10:30  Selecting Candidates for Focal Ablation: MRFTB vs Saturation Template Biopsy
Mark Emberton, MD, FRCS

10:50  Energy Sources for Ablating Prostate Cancer
James S. Wysock, MD, MS

11:20  Selecting an Energy Source Case By Case
Mark Emberton, MD, FRCS

11:40  Selecting an Energy Source Case By Case
Samir S. Taneja, MD

12:00 PM  Lunch (on your own)

1:15  Focal HIFU: The European Experience
Mark Emberton, MD, FRCS

1:45  Focal Cryo: The US
Samir S. Taneja, MD

2:05  Technical Pearls for Focal Cryo and HIFU
Stephen M. Scionti, MD

2:45  Starting a Focal Ablation Program
Herbert Lepor, MD

3:00  Moderator: Herbert Lepor, MD
Case Presentations
Marc A. Bjurlin, DO
Mark Emberton, MD, FRCS
Jurgen J. Futterer, MD, PhD
Eric A. Klein, MD
Stephen M. Scionti, MD
Samir S. Taneja, MD
James S. Wysock, MD, MS

4:00 PM  Adjourn

Register online at: med.nyu.edu/cme/prostate
Advances in Prostate Imaging, Detection and Ablative Treatment of Prostate Cancer

Friday, June 16–Saturday, June 17, 2017
New York City

Register online at:
med.nyu.edu/cme/prostate